PATENT CLAIM ANALYSIS

Application Number: 15746966
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-11
Patent Classification: ["544", "331000"]

Abstract:
Provided is an EGFR inhibitor and a pharmaceutically acceptable salt and a polymorph thereof, and a use thereof. In particular, provided is a polymorph, a pharmaceutically acceptable salt or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl)-5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino)-4-methoxy phenyl) acrylamide. In addition, also provided is a pharmaceutical composition containing the inhibitor and a use thereof.

Claim (Index 3):
The compound of  claim 1 , or a pharmaceutically acceptable salt, or a prodrug thereof, wherein the compound of formula X or a pharmaceutically acceptable salt thereof is crystal.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 86.0
- Lexical Diversity: 1.85366
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16098103', '13019262', '15753993', '14631712', '15571582']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.75490353825236
- 35 USC 102 Novelty (BERT): 0.5582838418707854
- Combined Prediction Score: 0.7352415686142026
- Mean Citation Score: 313.714576
- Max Citation Score: 425.19266
- Similarity Product: 346.0552304210592

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test